Prospective Study of Long-Term Impact of Adjuvant High-Dose and Conventional-Dose Chemotherapy on Health-Related Quality of Life
Authors:
- 1 December 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (34) , 5403-5409
Abstract
Purpose: To evaluate and compare health-related quality of life (HRQOL) after conventional- and high-dose adjuvant chemotherapy in patients with high-risk breast cancer. Patients and Methods: Patients were randomly assigned to either a conventional or high-dose chemotherapy regimen; both regimens were followed by radiotherapy and tamoxifen. HRQOL was evaluated until disease progression using the Short Form-36 (SF-36), Visual Analog Scale, and Rotterdam Symptom Checklist and assessed every 6 months for 5 years after random assignment. For the SF-36, data from healthy Dutch women with the same age distribution served as reference values. Results: Eight hundred four patients (conventional-dose chemotherapy, n = 405; high-dose chemotherapy, n = 399) were included. Median follow-up time was 57 months. Directly after high-dose chemotherapy, HRQOL decreased more compared with conventional chemotherapy for all SF-36 subscales. After 1 year, the reference value of healthy women was reached in both groups. Small differences were observed between the two groups in the role-physical and role-emotional subscales, but 1 year after treatment, these differences were minor and not clinically relevant. During follow-up, patients with a lower educational level and many complaints before chemotherapy experienced a worse HRQOL. Conclusion: Shortly after high-dose chemotherapy, HRQOL was more affected than after conventional-dose chemotherapy. One year after random assignment, differences were negligible. Identifying patients who have a higher chance of persistent impaired quality of life after treatment (which, in the present study, included patients with a lower educational level and many complaints before chemotherapy) is important and may open the way for better patient-tailored prevention strategies.Keywords
This publication has 24 references indexed in Scilit:
- High dose chemotherapy for poor prognosis breast cancer: Systematic review and meta-analysisCancer Treatment Reviews, 2007
- Quality of life among patients with Stage II and III breast carcinoma randomized to receive high‐dose chemotherapy with autologous bone marrow support or intermediate‐dose chemotherapyCancer, 2005
- A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantationBone Marrow Transplantation, 2005
- Quality of Life in Women With Breast Cancer During the First Year After Random Assignment to Adjuvant Treatment With Marrow-Supported High-Dose Chemotherapy With Cyclophosphamide, Thiotepa, and Carboplatin or Tailored Therapy With Fluorouracil, Epirubicin, and Cyclophosphamide: Scandinavian Breast Group Study 9401Journal of Clinical Oncology, 2003
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast CancerNew England Journal of Medicine, 2003
- Quality of life in patients undergoing systemic therapy for advanced breast cancerThe Lancet Oncology, 2002
- Quality of Life in Long-Term, Disease-Free Survivors of Breast Cancer: a Follow-up StudyJNCI: Journal of the National Cancer Institute, 2002
- Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancerBone Marrow Transplantation, 2001
- Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow supportPsycho-Oncology, 1999
- Quality of life following bone marrow transplantation for breast cancer: a comparative studyBone Marrow Transplantation, 1997